FibriCheck US is a prescription-only medical device for smartphone-based heart rhythm assessment and clinical reporting.
The App DNA
What makes this app unique?
Users report: It replaces the need for external hardware in cardiac monitoring by utilizing the smartphone camera for clinical-grade rhythm data capture.
For Patients diagnosed with or suspected of having cardiac arrhythmias who require longitudinal monitoring under the guidance of a healthcare professional.
What does it look like?
Key features
Uses the smartphone camera to measure heart rhythm and rate in 60 seconds without external hardware.
Generates summarized rhythm strips and AF load data for physician review.
API-based connectivity with existing electronic health records and population health systems.
How much does it cost?
The app operates on a prescription-only model, requiring physician authorization to activate, which aligns with its status as a regulated medical device.
Velocity
Dormant developmentopaqueShow more...
FibriCheck US has entered a zombie state, with no new feature builds or updates released in the last 294 days. The development momentum has completely stalled, as the only recorded activity in the analyzed window is a single minor update from late 2025. There is no evidence of ongoing maintenance or active support for the platform.
Who built it?
User Sentiment
What do users think recently?
How are ratings & reviews evolving?
Not enough recent reviews to extract reliable themes yet.
Read the full review analysisCompetition
Competitive landscape for FibriCheck US
How's the Medical market?
FibriCheck US operates in the regulated medical device space, where its clinical validation (FDA 510(k) K232804) serves as the primary differentiator against consumer-grade heart rate apps. The lack of recent updates (9 months) signals a maintenance-mode posture that leaves the app exposed to faster-moving wearable competitors.
Read the market outlookThe rivals identified
Unlock the deeper market read.
Access the full report for freeThe Analyst's Read
Key takeaways for FibriCheck US
Where is it heading?
The medical device market is shifting toward integrated diagnostic tools that bridge the gap between patient-led monitoring and clinical EHR systems. FibriCheck US remains advantaged by its regulatory status, but the lack of recent development activity suggests the app is not currently capturing the growth potential of this shift.
- The 9-month update silence indicates a maintenance-only posture, which limits the ability to respond to new mobile OS requirements.
- FDA 510(k) clearance provides a defensible regulatory barrier that consumer wellness apps cannot easily replicate without significant clinical investment.
The SWOT
- FDA 510(k) clearance validates clinical rhythm monitoring mechanism
- EHR integration creates high switching costs for clinical partners
- Telehealth partnerships could expand the prescription activation funnel
Next best moves
Ship a maintenance release to ensure OS compatibility because the app has been dormant for 9 months → prevent technical churn
The counter-intuitive read
The prescription-only model is a strength, not a barrier…
Read the full takeSince the last report: The report now explicitly anchors the app's competitive position to its FDA 510(k) clearance (K232804), moving from general clinical validation to specific regulatory status. Development remains in a maintenance-only state with no new feature releases.
Bottom line
FibriCheck US relies on its clinical validation to maintain its position, but the 9-month update silence risks technical obsolescence. Prioritizing a maintenance release to ensure compatibility with the latest mobile operating systems would protect the existing clinical integration pipeline.
Unlock 2 critical frictions, 1 market threat and the analyst’s take.
Access the full report for freeSources
- [1] App Store listing, source
Report last updated